BioSpace News Archive

Despite a sharp downturn in initial public offering activity, New York-based gene therapy company Lexeo Therapeutics and French biotech Abivax are seeking funding for their lead candidate programs.

Eli Lilly’s Biologic License Application for its monoclonal antibody lebrikizumab was denied by the regulator after issues were found at a third-party contract manufacturing organization.

Judge Michael Newman of the Southern District of Ohio issued a ruling Friday denying the U.S. Chamber of Commerce’s request for a preliminary injunction against the Inflation Reduction Act provisions.

Shares of the biotech startup jumped as much as 70% on Friday after the company reported promising early-stage results for a four-week trial that included only 24 patients.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced that the US Food and Drug Administration has accepted for filing the New Drug Application for the antibiotic ceftobiprole, which was submitted to the FDA on August 3rd this year.

Pneumagen announced positive results from its Phase 2, Proof of Concept, Controlled Human Infection Model study where patients were challenged with influenza virus following administration of Neumifil.

DexCom, Inc. announced new clinical study outcomes that further demonstrate the benefits of CGM use and offered more details about its expanding portfolio of automated insulin delivery offerings at the 59th Annual Meeting of the European Association for the Study of Diabetes held Oct. 2-6, 2023 in Hamburg, Germany.

Broken String Biosciences announced the expansion of its senior leadership team with the appointments of Vincent Smith, PhD, as Chief Technology Officer and Jessica Rich as VP Business Development.

Opthea Limited announced that on October 4th, Dr. Megan Baldwin, the Company’s Chief Executive Officer will be a panelist at the inaugural Euretina Innovation Spotlight forum which is part of the Organization’s 23rd Congress being held on October 5th – 8th in Amsterdam, The Netherlands.

The OpenFold group, a non-profit artificial intelligence research consortium of biotech and tech firms whose goal is to develop free and open-source software tools for biology and drug discovery, is announcing the funding of new large-scale protein studies at Prof. Gabriel Rocklin’s laboratory at Northwestern University.